Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA
The available human studies do not support the role of Ginkgo biloba as a treatment for cancer, but the published studies were not placebo-controlled, making it difficult to draw conclusions from the data.
Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.
While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.
In vivo studies suggest that extracts of St John's wort may have apoptotic effects on cancer cells, but human studies have not been conducted to test this hypothesis.
Vitamin E supplementation appears to reduce the risk of chemotherapy-induced neurotoxicity and several radiation-induced toxicities, though one study found increased recurrence rates with its use.
More Articles by Andrea S. Blevins Primeau, PhD, MBA
Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast CancerSep 08,2017
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC
- Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC